$GKOS

Navratil Tomas sold $201K of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 1,537 shares of GLAUKOS Corp (GKOS) at $130.68 ($0.20M total) on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Navratil Tomas
Published Jun 18, 2026, 11:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The disclosed sale is a concrete, newly filed datapoint that can influence short-term sentiment, but the 10b5-1 structure generally limits inference about near-term fundamentals.

02

Market read

Traders may monitor GKOS for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

The filing date may lag the actual sale; traders should avoid over-weighting the disclosure versus the execution date and consider whether there are concurrent insider buys/sales or upcoming company-specific events.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-18 after-hours; reflects sale executed 2026-06-16.

Background

This is an SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by an officer, including execution details and confirmation of a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS chief development officer Navratil Tomas sold 1,537 shares for about $200,855 on 2026-06-16 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely muted and short-lived.

Evidence & confidence

The transaction is an open-market sale by an officer and explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild caution signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • GLAUKOS Corp

    Subject of the Form 4 insider transaction disclosure (GKOS).

  • Navratil Tomas

    Chief Development Officer who sold 1,537 shares under a 10b5-1 plan.

Related articles

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

$GKOSHighAI 9/10

Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up

Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.

$GKOSMed

Glaukos Q2 Earnings Call Highlights

Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.

$GKOSMedAI 8/10

GLAUKOS Corp (GKOS): Results of Operations and Financial Condition

GLAUKOS Corp (GKOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 gkos-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 JULY 29, 2026 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2026 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designe

$GKOSMed

Midday Stock Roundup: Glaukos Rises

A midday roundup highlights multiple movers. V.F. Corp. (VFC) fell 17% to $15.24 after lower first-quarter revenue tied to weakness in Vans and CFO Paul Vogel leaving. Envista (NVST) rose 6.2% to $28.63 ahead of an Sept. 17 investor day. Glaukos (GKOS) gained 7.9% to $159.25 after completing patient enrollment in a 510(k) glaucoma study.